ERBB2 and breast carcinoma: Here we demonstrate using two well-characterized transgenic mouse models of ErbB2 breast cancer that while the presence of functional FAK confers a proliferative advantage to ErbB2 tumour cells, metastatic ErbB2 mammary tumours can be generated in the complete absence of FAK expression.